Accepted for/Published in: JMIR Medical Informatics
Date Submitted: Mar 12, 2020
Date Accepted: Mar 22, 2020
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Research on Artificial Intelligence-based Technology in Assisted formulation of Oral Drug Treatment Strategies for Geriatric Diabetes Drugs
ABSTRACT
Background:
This paper studies the application of artificial intelligence techniques in the diagnosis of diabetes.
Objective:
This paper studies the application of artificial intelligence techniques in the diagnosis of diabetes.
Methods:
This paper established based on BP neural network diagnostic model of artificial intelligence technology, data collected on the case of integration and extraction, select the input feature vector, to establish the diagnosis model in MATLAB software platform. Meanwhile, based on the diagnostic model, based on the LabVIEW development platform and intelligent combination of MATLAB software designed diabetes diagnosis system., User data by calling the neural network diagnostic module analyzes, to complete the diagnosis of diabetes, and gives appropriate treatment recommendations.
Results:
Compared to the conventional diagnostic procedure, the system can effectively save time doctor to improve diagnostic efficiency.
Conclusions:
The artificial intelligence in older diabetes drugs oral drug treatment strategies assist in the development of applications have some utility.
Citation
The author of this paper has made a PDF available, but requires the user to login, or create an account.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.